Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.
Clinical trial NCT05411380 · UNKNOWN
Trial details
- NCT number
- NCT05411380
- Sponsor
- wang shusen
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-03
- Primary completion
- 2024-04-01
- Enrollment
- 73
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.